SLIDE 1
Cancers for Disease Control and Prevention
Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness - - PowerPoint PPT Presentation
Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness - - PowerPoint PPT Presentation
Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness and Anti EGFR Retreatment Benjamin A. Weinberg, M.D. Assistant Professor of Medicine Lombardi Comprehensive Cancer Center Georgetown University LEFT RIGHT Cancers for
SLIDE 2
SLIDE 3
Weinberg et al. Oncology (Williston Park) 2017.
Younger Individuals Tend to Have Left-Sided CRCs
SLIDE 4
CALGB/SWOG 80405: KRAS wt
Presented By Alan Venook at 2017 ASCO Annual Meeting
SLIDE 5
<br /> 80405: (KRAS WT) Overall Survival by Sidedness
Presented By Alan Venook at 2017 ASCO Annual Meeting
SLIDE 6
80405 (KRAS WT): Overall Survival by Sidedness and Biologic
Presented By Alan Venook at 2017 ASCO Annual Meeting
SLIDE 7
Right vs. Left Colon vs. Rectum
Salem et al. Oncotarget 2017.
SLIDE 8
Right vs. Left Colon vs. Rectum
Salem et al. Oncotarget 2017.
SLIDE 9
NCCN Guidelines 3.2019. JNCCN 2019.
SLIDE 10
NCCN Guidelines 3.2019. JNCCN 2019.
SLIDE 11
Brulé et al. Eur J Cancer 2015.
KRAS-WT: Right vs. Left Primary Tumors NCIC CO.17 Trial
SLIDE 12
Loree et al. GI ASCO 2019.
SLIDE 13
Re-Challenging with anti-EGFR Therapy
- May not work as well patients who
progressed on anti-EGFR therapy previously (more useful in those who discontinued due to toxicity)
- Need to ensure tumor is still RAS and BRAF
wild type
- COLOMATE (liquid biopsy) PULSE study
(panitumumab re-challenge)
SLIDE 14
Questions?
- baw12@gunet.georgetown.edu
- @benweinbergmd